Pharmaceutical Articles & Analysis

The American Food and Drug Administration (FDA) has granted Orphan Drug Designation to ZENEO® Midazolam for the treatment of status epilepticus (epileptic seizure lasting longer than 5 minutes). The orphan designation for ZENEO® Midazolam improves Crossject’s international visibility and gives impetus to its current negotiations for partnerships with pharmaceutical laboratories. ...

By Crossject

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. A webcast of ...

By Zynerba Pharmaceuticals, Inc.

Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing ...

By S&P Global Platts

T3 Pharma has been awarded the CTI Start-up Label by the Commission for Technology and Innovation CTI. The label is the result of a coaching process that allowed T3 Pharma to refine its corporate strategy. T3 Pharma is honored to have received the Start-up Label which is "a seal of quality, a certificate of achievement, and a sign of credibility and readiness for sustainable growth". ...

By T3 Pharmaceuticals AG

Under the leadership of the Chairman Mr. Zhao Ding, Seacross attended the CPHI held in Frankfurt from November 05th to 07th, 2019. This is the largest pharmaceutical trade show in the world. At CPHI, a steady stream of visitors came to Seacross’s Stand and showed great interest in establishing working relationships. Our Stand received representatives from more than one hundred interested ...

By Seacross Pharmaceuticals Ltd

ARLINGTON, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the largest Pharmacy Benefit Manager in the United States has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as ...

By Kala Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) and Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. OXLUMO, which has been approved by the ...

By Dicerna Pharmaceuticals, Inc.

Lipella Pharmaceuticals’ LP-310 asset has the potential to become the first oral drug treatment for oral lichen planus Pittsburgh, PA – (May 11, 2021) – Lipella Pharmaceuticals Inc., a clinical stage pharmaceutical company based in Pittsburgh, PA, announced today that the company has successfully concluded a Type B pre-Investigational New Drug (IND) meeting communication with ...

By Lipella Pharmaceuticals Inc.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021. As previously announced on November 18, 2021, Novo Nordisk commenced a cash tender ...

By Dicerna Pharmaceuticals, Inc.

Healthy aging - one size does not fit all. Read this provocative article about the need for an integrative, preventive, and tailored approach that combines lifestyle and appropriate pharmaceutical intervention. The article appeared in the Winter edition of American Academy of Anti Aging Medical News. ...

By Incogen, Inc.

AT-Patch is distributed to domestic clinics through Hanmi Pharmaceutical Co., Ltd. Expect to expand ATsens' product line with this Strategic MOU ...

By ATsens Co., Ltd.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 31,875 shares of common stock and 7,125 restricted ...

By Dicerna Pharmaceuticals, Inc.

China-Japan Advanced Medical and New Drug R & D Summit Forum and Achievement Transformation Conference” was held in Chengdu, sponsored by Sichuan international medical exchange promotion association and Kobe translational medicine research center (TRI). This conference aims to promote win-win cooperation between the biomedical industries of China and Japan, and realize the ...

By Seacross Pharmaceuticals Ltd

Norgenix Pharmaceuticals, LLC, and CrossBay Medical, Inc. today announced a strategic alliance and revealed its medical device co-promotion, the SonoSure™ Sonohysterography and Endometrial Sampling ...

By CrossBay Medical

Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced a partnership with Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading pharmaceutical company in the Middle East and North Africa (MENA), to commercialise select speciality products in the Middle East. Under the terms of this ...

By Biocon

ARLINGTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. ...

By Kala Pharmaceuticals, Inc.

MISSISSAUGA, ONTARIO (May 10, 2022) BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2022 on Wednesday, May 18, 2022 at 8:00am ET. A presentation on the Company’s first quarter 2022 results by René Goehrum, BioSyent President and CEO, will also be available on the ...

By BioSyent Pharma Inc.

New 344,000 square foot cell and genetic therapies research and manufacturing facility to be built Facility to support continued R&D growth At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced plans to build another 344,000 square foot facility in the Seaport to ...

By Vertex Pharmaceuticals

Huateng Pharma, a leading innovator in pharmaceutical intermediates, is proud to announce the introduction of its latest product line - Gastrointestinal API Intermediates, featuring the groundbreaking compounds Fexuprazan and Vonoprazan Intermediates. These cutting-edge substances have been meticulously developed to meet the growing demands of the pharmaceutical industry. Fexuprazan Intermediates ...

By Hunan Huateng Pharmaceutical Co. Ltd.

ARLINGTON, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 15,000 shares of ...

By Kala Pharmaceuticals, Inc.